GreenApple78/iStock via Getty Images BridgeBio ( NASDAQ: BBIO ) released additional positive data for its drug acoramidis in the treatment of ATTR-CM, a type of heart failure. The biotech company said the data included the results of five new analyses of clinical data endpoint events from its Phase 3 study of the drug called ATTRibute-CM. The data showed acoramidis increased serum TTR levels by day 28 that were correlated with a reduced risk of all-cause mortality, cardiovascular mortality and cardiovascular-related hospitalization in ATTR-CM patients through month 30, according to the company .
Researchers presented the analyses at the 2024 International Symposium of Amyloidosis. BridgeBio said it was hosting an investor call Wednesday afternoon to discuss the data. The FDA has a target action date of Nov.
29 for BridgeBio’s market application for acoramidis in the treatment of ATTR-CM. EU regulators are expected to issue a decision in 2025. Pfizer ( PFE ) also has a drug to treat ATTR-CM called tafamidis.
The drug is marketed under the brand names Vyndamax and Vyndaqel. More on BridgeBio Pharma BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident Cantor picks 14 undervalued biotech stocks worth a second look BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.
31, revenue of $211.12M beats by $127.34M Seeking Alpha’s Quant Rating on BridgeBio Pharma Historical earnings data for BridgeBio Pharma.
